National Drug Policy Face-off: Some Notes Justifying the Regulations and Drug Price Control Regime in India

Motkuri, Venkatanarayana and Mishra, Rudra Narayana (2018): National Drug Policy Face-off: Some Notes Justifying the Regulations and Drug Price Control Regime in India.

Abstract

This is an attempt in examining and carrying out the discussion and debate on regulations and prince control in pharmaceutical industry in the Indian context. Herein the above discussion presented the perspectives of the industry and the welfare of the poor population along with alternative options. Given its critical nature in existence of human race while protecting, maintaining and restoring health of human being, regulations on pharmaceutical industry are needed to ensure safety, quality and effectiveness of drugs they develop and produce. As pharmaceutical industry involved with the phenomenon of Induced-demand and it is one of the industries where the price competition may not be prevailing, hence price controls on certain essential and life-saving drugs are needed especially in the Indian context.

• Item Type: MPRA Paper
• Language: English
• Keywords: Drugs, Pharmaceuticals, Industry, India, Drug Development, Drug Discovery, Drug Marketing, Pharmaceuticalisation, Drug Regulations, Drug Price Control
• Subjects: I - Health, Education, and Welfare > I1 - Health > I10 - General; I - Health, Education, and Welfare > I1 - Health > I11 - Analysis of Health Care Markets; I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health

References

AdvaMed (2017). Medical Devices Industry in India: The Evolving Landscape, Opportunities and Challenges, SKP and Advanced Medical Technology Association (AdvaMed), Report dated 09/29/2018, Accessed at: https://www.advamed.org/sites/default/files/resource/medical_industry_in_india_-_the_evolving_landscape_oppurtunities_and_challenges_white_paper.pdf

AdvaMed (2018). Medical Devices in India: An Agenda to Effective Health Care Delivery, IQVIA and Advanced Medical Technology Association (AdvaMed). Report Dated 01/24/2018, Accessed at: https://www.advamed.org/resource-center/medical-devices-india-agenda-effective-healthcare-delivery

Ahmad, Akram; Muhammad Umair Khan and Isha Patel (2015). “Drug Pricing Policies in one of the large Drug Manufacturing nations in the World: Are affordability and access a cause for concern?”, Journal of Research in Pharma Practices, Vol. 4 (1), Jan-Mar, pp.1-3.

Bhattacharjea, Aditya and Fiyanshu Sindhwani (2014). Competition Issues in the Indian Pharmaceuticals Sector, Centre for Development Economics, Delhi School of Economics, Delhi. Project Sponsored by CUTS-CIRC.

Centad (2010). Competition Law and Indian Pharmaceutical Industry, Centre for Trade and Development (Centad), New Delhi. Accessed at: http://www.cci.gov.in/sites/default/files/PharmInd230611_0.pdf.

Currie, J.; W. Lin and W. Zhang (2010). “Patient knowledge and antibiotic abuse: Evidence from an audit study in China”, Journal of Health Economics, Vol. 30, pp.933–949.

D’Souza, J.B. (2006). “Drug Prices and Drug Pushers”, Commentary, Economic and Political Weekly, Vol. 41 (21), May 27.

Dhar, Biswajit and Reji K. Joseph (2014). “Developments in India’s Domestic Pharmaceutical Sector”, Chapter 13 in India Social Development Report 2014: Challenges of Public Health, edited by Imraan Quadeer, OUP, New Delhi.

DiMasi, J. A.; H. G. Grabowski; and R. W. Hansen (2016). “Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs”, Journal of Health Economics, Vol. 47, pp.20-33, doi: 10.1016/j.jhealeco.2016.01.012

DiMasi, J. A.; R. W. Hansen; H. G. Grabowski; and Louis Lasagna (1991). “Cost of Innovation in the Pharmaceutical Industry”, Journal of Health Economics, Vol. 10, pp.107-142.

EPW (2014). “Mala Fide Decision on Drug Prices”, Editorial, Economic and Political Weekly, Vol. 49 (42), October 18.

EPW (1965). "Drug Prices: Case for Enquiry", Editorial, Economic and Political Weekly, Vol. x(x), January 16, 1965.

EvaluatePharma (2017). World Preview 2017: Outlook to 2022, EvaluatePharma.

Fuchs, V. R. (1996). “Physician-Induced Demand: A Parable”, Journal of Health Economics, Vol. 5, pp. 367-380.

Gadre, Arun and Nilangi Sardeshpande (2017). “Cut Practice in Private Healthcare”, Commentary, Economic and Political Weekly, Vol. 52 (48), December 2.

Gandhi, Feroze Varun (2016). “Drug Pricing: a Bitter Pill to Swallow”, Column, The Hindu, February 26.

GOI (1959). Report on the Revision of the Patents Law (known as Ayyangar Committee Report), Government of India, New Delhi.

GOI (1975). Report of the Committee on Drugs and Pharmaceutical Industry (known as Hathi Committee Report), Ministry of Petroleum and Chemicals, Government of India, New Delhi, April.

GOI (2005). Report of the Task Force to Explore Options other than Price Control for Achieving the Objective of Making Available Life-saving Drugs at Reasonable Prices (Pronab Sen Task Force Report), Department of Chemicals and Petrochemicals, Ministry of Fertilisers and Chemicals, Government of India, New Delhi, September.

GOI (2016). Report on Pricing of Stents, Government of India, New Delhi.

GOI (2018). Economic Survey 2017-18, Economic Division, Department of Economic Affairs, Ministry of Finance, Government of India, New Delhi.

Hooper, Charles L. (2007). “Pharmaceuticals: Economics and Regulation”, in The Concise Encyclopedia of Economics (2nd edition) edited by David R. Henderson, The Library of Economics and Liberty, The Liberty Fund Inc. Available at http://www.econlib.org/library/Enc/PharmaceuticalsEconomicsandRegulation.html

IBEF (2017). “Sector Report: Pharmaceutical”, Indian Brand Equity Foundation (IBEF), October.

ICMR/PHFI/IHME (2017). India: Health of the Nation’s States- Disease Burden Trends in the States of India 1990 to 2016, November, Indian Council of Medical Research (ICMR), Public Health Foundation of India (PHFI) and Institute of Health Metrics and Evaluation (IHME), New Delhi. Accessed at: http://icmr.nic.in/publications/India_Health_of_the_Nation%27s_States_Report_2017.pdf

IFPMA (2017). The Pharmaceutical Industry and Global Health: Facts and Figures 2017, International Federation of Pharmaceutical Manufacturers and Associations, Geneva, February. Accessed at: https://www.ifpma.org/wp-content/uploads/2017/02/IFPMA-Facts-And-Figures-2017.pdf.

Johnson, E.M. (2014). “Physician-Induced Demand”, in Encyclopedia of Health Economics, Vol. 3, xxx. Available at : https://pdfs.semanticscholar.org/ac7d/de18b09bf20c2c1da82067355a76563e6325.pdf

Joseph, Reji K. (2016). Pharmaceutical Industry and Public Policy in Post-Reform India, Critical Political Economy of South Asia series, Routledge, New Delhi.

Kamiike, Atsuko; Chiranjib Neogi and Takahiro Sato (2014). “Factor behind the Performance of Pharmaceutical Industries in India”, Economic and Political Weekly, Vol. 49 (52), December 27.

Khan, Amir Ullah (2017). “When Pharma Pricing Regulator Turned Bat-bully: NPPA Price Capping Shook Industry, Now here is What is Worsening Situation”, Financial Express, October 27.

Lakdawalla, D.N.; D.P. Goldman; P-C Michaud; N. Sood; R. Lempert; Z. Cong; H. de Vries; and I. Gutierrez (2009). “U.S. Pharmaceutical Policy in a Global Marketplace”, Health Affairs, Vol. 28, No. 1, January 2009.

Lalitha N. (2005). “Review of the Pharmaceutical Industry of Canada”, Economic and Political Weekly, Vol. 40 (13), March 26.

Mazumder, Pradip (2017). “The Generic Manoeuvre”, Commentary, Economic and Political Weekly, Vol. 52 (35), September 2.

Mondal, Shamim S. and Viswanath Pingali (2015). “Competition Law and Pharmaceutical Sector in India”, WP No. 2015-11-02, Indian Institute of Management, Ahmadabad. Accessed at http://vslir.iima.ac.in:8080/jspui/bitstream/11718/17052/1/Pingali2015.pdf.

Mudur, G.S. (2017). “Profiteer Slur on Hospital”, The Telegraph, December 17. Accessible at https://www.telegraphindia.com/india/profiteer-slur-on-hospital-194206#.WjfbPRTVnXR.gmail

Mulinari, Shai (2016). “Regulating Pharmaceutical Industry Marketing: Development, Enforcement and Outcome of Marketing Rules”, Sociology Compass, Vol. 10 (1), January 6, pp. 74-86.

Nair, Arvind (1965). “Drug Prices: Is there a Case for Enquiry?”, Economic and Political Weekly, Vol. x (x), April 3.

Nordia (2016). Impacts of Pharmaceutical Pollution on Communities and Environment in India, Report Prepared for Nordea Asset Management by Changing Markets And Ecostorm. Accessed at: https://www.nordea.com/Images/35-107206/impacts%201-20.pdf

Nundy, M and Rama Baru (2013). “Recent Trends in Health Sector Reforms and Commercialisation of Public Hospitals in China”, Institute of Chinese Studies Working paper 013/12/2, Accessed at http://www.icsin.org/uploads/2015/04/12/3f84446dce7db66dc13bfb648dab5aea.pdf.

Nundy, Madhurima and Rama V. Baru (2015). “Lifting Drug Price Controls in China”, Economic and Political Weekly, Web Exclusive, Vol. 50 (22), May 30.

Phadke, Anant; S. Srinivasan and T. Srikrishna (2013). “As Good As a Leaky Bucket: The Drug Price Control Order 2013”, Commentary, Economic and Political Weekly, Vol. 48 (26-27), June 29.

Raghavan, Prabha and Divya Rajagopal (2017). “Health Care’s Dilemma: Balancing Public Needs with Business Sense”, Economic Times Bureau, Economic Times, November 30. Accessed at https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/healthcares-dilemma-balancing-public-needs-with-business-sense/amp_articleshow/61855883.cms

Rajagopal, D. (2016). “Policy bumps may hit pharmaceutical market’s dream run”, ET Bureau, March 22, The Economic Times. Available from: http://economictimes.indiatimes.com/industry/ healthcare/biotech/pharmaceuticals/policy-bumps-may-hit-pharmaceuticalmarkets-dream-run/articleshow/51504576.cms.

Rand (2008). “Regulating Drug Prices: US Policy Alternatives in the Global Context”, Rand Research Highlights, Rand Health, Rand Corporation, California.

Rane, Wishvas (1996). “Analysing Drug Prices, 1980 to 1995”, Economic and Political Weekly, Vol. 31 (34), August 24.

Rane, Wishvas (2002). “Marginal Rise in Cardiovascular Products: Prices of Prescription Drugs”, Commentary, Economic and Political Weekly, Vol. 37 (33), August 17.

Ranganathan, Thiagu (2017). “Antibiotic Treatments for Short-term Morbidity in India”, Economic and Political Weekly, Vol. LII (47), November 25.

Rangarao, B.V.; P.K. Ramachandran and P.S. Agarwal (1972). Anomalies in Drug Prices and Quality Control”, Economic and Political Weekly, Vol. 7 (46-47), November 18.

Selvaraj, S. (2007). “How Effective Is India's Drug Price Control Regime?”, Boston, MA, USA: Harvard School of Public Health; 2007. Available at: https://www.hsph.harvard.edu/wp-content/uploads/sites/114/2012/10/RP256.pdf.

Selvaraj, Sakthivel; Dinesh Abrol; and K.M. Gopakumar (eds.) (2014). Access to Medicines in India, Academic Foundation and ISID, New Delhi.

Sood, Neeraj; Han de Vries; Italo Gutierrez; Darius N. Lakdawalla, and Dana P. Goldman (2009). The Effect of Regulation on Pharmaceutical Revenues: Experience In Nineteen Countries, Rand Health Affairs, Vol. 28 (1) Rand Corporation, California.

Srinath Reddy K; B. Shah B; C. Varghese; A. Ramadoss (2005). “Responding to the threat of chronic diseases in India”, Lancet, Vol. 366, pp:1744–9.

Srinivasan, S. (2001). “Drug Price Control”, Commentary, Economic and Political Weekly, Vol. 36 (12), March 24.

Srinivasan, S. (2017). “Why Is the Draft Pharmaceutical Policy Shaking up India’s Drug Price Regulator?”, The Wire, 29/08/2017.

Sweetman, Andrew (2017). “The Medical Costs Act – What it means for Pharma”, The Pharmaceutical Journal, Vol 299 (7906), October 19.

Trivedi, Isha (2017). “Fading Glory: Indian Pharma Industry in Unchartered Terrain”, Live Mint, June 23. Accessed at http://www.livemint.com/Industry/FsuFVKI1dNC30O4TyWeOGO/Fading-glory-Indian-pharma-industry-in-uncharted-terrain.html.

Unnikrishnan, C. H. (2012). “New Drug Pricing Policy may hit Profitability of Firms”, Live Mint, December 11. Accessed at http://www.livemint.com/Industry/thYjee2K9jiIVshL6zQZ0O/New-drug-pricing-policy-may-hit-profitability-of-firms.html

WHO (2005). Containing Anti-Microbial Resistance, WHO Policy Perspective on Medicine 10, World Health Organisation, Geneva.

WHO (2008). Measuring medicine prices, availability, affordability and price components, World Health Organisation (WHO), Geneva.

WHO (2010). Continuity and Change: Implementing the third WHO Medicines Strategy 2008-2013, WHO Policy Perspective on Medicine 11, World Health Organisation, Geneva.

WHO (2011). The World Medicines Situation Report 2011, World Health Organisation, Geneva.

WHO (2016). The WHO Health Systems Framework, Geneva: World Health Organization. Accessible at: http://www.wpro.who.int/health_services/health_systems_framework/en.

WHO (2017). Responding to Industry Initiatives to Increase Access to Medicines and Other Health Technologies in Countries, EMP Policy Brief Series No. 2.0, Essential Medicine and Health Products (EMP), World Health Organisation, Geneva.

Woolcock, Michael (1998). “Social capital and economic development: Toward a theoretical synthesis and policy framework”, Theory and Society, Vol. 27, pp: 151-208.